Perjeta: payments to doctors
Payments that named Perjeta as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $55.6M
- Providers
- 4,492
- Transactions
- 11,401
- Average per transaction
- $4,878
The per-transaction average — $4,878 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,492 providers the average total is $12,381, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $54,506,875 | 98.0% |
| Genentech USA, Inc. | $892,731 | 1.6% |
| F. Hoffmann-la Roche AG | $185,688 | 0.3% |
| Chugai Pharmaceutical Co., Ltd. | $27,385 | 0.0% |
| Hoffmann-la Roche Limited | $1,320 | 0.0% |
| Roche Products Limited | $870 | 0.0% |